Detalles de la búsqueda
1.
Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
Oncologist
; 24(11): 1497-1501, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31399500
2.
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Cancer
; 122(24): 3856-3864, 2016 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27525386
3.
Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial.
Eur J Cancer
; 168: 91-98, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35487183
4.
A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.
Thyroid
; 32(5): 515-524, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35403447
5.
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.
Eur Urol
; 75(6): 929-937, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30528222
6.
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
Eur J Cancer
; 94: 115-125, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29550566
7.
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
J Clin Oncol
; 36(8): 757-764, 2018 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29377755
8.
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].
Eur J Cancer
; 103: 287, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30270112
Resultados
1 -
8
de 8
1
Próxima >
>>